Analysts impressed as J&J acquires $1 billion stake in Elan In a deal warmly welcomed by analysts, Ireland’s Elan Corp has a sold a major stake in the firm and the rights to its portfolio of Alzheimer’s disease investigational drugs to Johnson & Johnson in return for $1 billion
Roche/Genentech to seek a new approval for Lucentis Roche’s Genentech unit has presented promising data which it hopes will result in an approval for a second indication of the sight drug Lucentis
